<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; Hospira</title>
	<atom:link href="http://www.tapanray.in/tag/hospira/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Is Fraud or Negligence in Drug Quality Standards Not a Fraud on Patients?</title>
		<link>http://www.tapanray.in/is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients</link>
		<comments>http://www.tapanray.in/is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients/#comments</comments>
		<pubDate>Mon, 03 Jun 2013 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Americans]]></category>
		<category><![CDATA[anywhere]]></category>
		<category><![CDATA[Baxter]]></category>
		<category><![CDATA[Boehringer]]></category>
		<category><![CDATA[branded]]></category>
		<category><![CDATA[breach]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[charitable]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Claris]]></category>
		<category><![CDATA[contamination]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Dewas]]></category>
		<category><![CDATA[Dr. Reddy's]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[everywhere]]></category>
		<category><![CDATA[facilities]]></category>
		<category><![CDATA[fraud]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Heparin]]></category>
		<category><![CDATA[Hospira]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[IMA]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[Ingelheim]]></category>
		<category><![CDATA[ingredients]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[Jaslok]]></category>
		<category><![CDATA[Jubilant]]></category>
		<category><![CDATA[Lupin]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Medical Association]]></category>
		<category><![CDATA[Mumbai]]></category>
		<category><![CDATA[OSCS]]></category>
		<category><![CDATA[paonta]]></category>
		<category><![CDATA[pew]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[plants]]></category>
		<category><![CDATA[prescription]]></category>
		<category><![CDATA[Project]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sahib]]></category>
		<category><![CDATA[Schering-Plough]]></category>
		<category><![CDATA[SCS]]></category>
		<category><![CDATA[Security]]></category>
		<category><![CDATA[Show]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[standards]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[tolerance]]></category>
		<category><![CDATA[tragedy]]></category>
		<category><![CDATA[trusts]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[wockhardt]]></category>
		<category><![CDATA[Wyeth]]></category>
		<category><![CDATA[zero]]></category>
		<category><![CDATA[Zydus]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2607</guid>
		<description><![CDATA[As we know, a substance is called a drug when it has scientifically proven and well documented efficacy and safety profile to reduce both mortality and morbidity of patients. Any fraud or negligence in the drug quality standards, for whatever &#8230; <a href="http://www.tapanray.in/is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-fraud-or-negligence-in-drug-quality-standards-not-a-fraud-on-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>More Glivec Like Deals in China and Mounting Global Challenges: Innovators poised Joining Biosimilar Bandwagon</title>
		<link>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon</link>
		<comments>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/#comments</comments>
		<pubDate>Mon, 15 Apr 2013 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[12years]]></category>
		<category><![CDATA[AbVie]]></category>
		<category><![CDATA[advantage]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[bandwagon]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Genentech]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Hospira]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[joining]]></category>
		<category><![CDATA[LG]]></category>
		<category><![CDATA[low]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Remicade]]></category>
		<category><![CDATA[Rituxan]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2164</guid>
		<description><![CDATA[Pressure from the emerging markets on pricing of patented products is mounting fast. This time the country involved is China. Recently, the Health Minister of China who stepped down last month after a seven-year stint in the top health job &#8230; <a href="http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
